Is vaginal estrogen the same as hormone replacement therapy?
No. Low-dose vaginal estrogen and systemic hormone therapy are not the same treatment, and confusing the two causes a lot of unnecessary worry. Low-dose vaginal estrogen is a local treatment for the genitourinary syndrome of menopause (GSM), the cluster of vaginal dryness, irritation, painful sex, and urinary symptoms that follows menopause. It works mostly where you place it and reaches the bloodstream in only tiny amounts. Systemic hormone therapy, taken as a pill, a skin patch, or a systemic-dose product, raises hormone levels throughout the body to treat whole-body menopausal symptoms such as hot flashes. They treat different symptoms and have different risk profiles.
How much gets into your bloodstream
With low-dose vaginal estrogen, serum estrogen levels stay within the normal postmenopausal range. Untreated postmenopausal women have estradiol levels of roughly 3 to 5 pg/mL, and a low-dose vaginal ring keeps it around 5 to 10 pg/mL. Systemic therapy is built to do the opposite, and serum estradiol rises higher with systemic treatment than with local estrogen. So while both contain estrogen, one stays local and one is meant to reach the whole body.
Why the absorption difference matters
Because so little is absorbed, low-dose vaginal estrogen is handled differently from systemic therapy in two practical ways. First, when low-dose vaginal estrogen is used, an added progestogen is not indicated, even for a woman who still has her uterus. That is a contrast with systemic estrogen, where a woman who still has a uterus is given a progestogen to protect the uterine lining. Second, routine endometrial surveillance is not recommended for women using low-dose vaginal estrogen, and guidelines advise against doing an ultrasound or biopsy solely because someone uses it. However, bleeding after menopause should always prompt an evaluation.
Does it help or hurt incontinence?
Local low-dose vaginal estrogen tends to modestly improve urinary symptoms. In a Cochrane review, vaginal estrogen improved incontinence, with a relative risk of 0.74, and in a separate systematic review it improved both stress and urgency incontinence compared with placebo. Systemic estrogen does the reverse. In the same Cochrane review, systemic estrogen worsened incontinence, whether it was given alone (relative risk 1.32) or with a progestogen (relative risk 1.11). Put plainly, the vaginal form may help a leaky bladder, while the systemic form has been shown to make leakage worse. If incontinence is one of your symptoms, let your doctor know when discussing hormonal treatments.
The FDA boxed warning
For years, low-dose vaginal estrogen products carried the same boxed warning as systemic hormone therapy, listing risks such as heart disease, stroke, blood clots, dementia, and breast and endometrial cancer. Those risks were seen in trials of systemic therapy, not measured for the low-dose vaginal products the warning was printed on, and menopause guidelines were explicit that they are highly unlikely to apply given how little vaginal estrogen is absorbed. In late 2025 the FDA agreed. After reviewing the evidence, it began removing the boxed-warning statements on cardiovascular disease, breast cancer, and probable dementia in November 2025, and on February 12, 2026 it approved the first round of updated labels, with topical vaginal estrogen among them. Reading a systemic warning on a local product had scared many women away from a treatment that would help them. Thankfully, that warning is now coming off the label.
Estring is not Femring
The word “ring” sometimes causes a specific mix-up. Estring is a low-dose, local vaginal ring. It releases about 7.5 micrograms of estradiol a day, treats GSM only, and keeps serum estradiol around 8 pg/mL. Femring looks similar but delivers a systemic dose meant to treat whole-body symptoms as well. Same shape, same body part, very different treatment. So if someone says they “use the ring,” it is worth knowing which one they mean.
Can you use both?
Yes. The two are not mutually exclusive. A woman on systemic hormone therapy who still has bothersome vaginal or urinary symptoms can add low-dose vaginal estrogen, and menopause and urology guidelines specifically support offering it in that situation.
How I approach it
When a patient has been scared off by the label, a good part of the visit is just untangling these two treatments. If the main problem is dryness, painful sex, or recurrent urinary symptoms, the local form is the best option, and the systemic warnings on the box are not describing what she would actually be using. If hot flashes are also disrupting her life, that is a separate conversation about systemic therapy, with its own trade-offs.
References
- Kaufman MR, Ackerman AL, Amin KA, et al. Genitourinary Syndrome of Menopause: AUA/SUFU/AUGS Guideline. American Urological Association. 2025.
- Faubion SS, Kingsberg SA, Clark AL, et al. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020. doi:10.1097/GME.0000000000001609
- Rahn DD, Carberry C, Sanses TV, et al. Vaginal Estrogen for Genitourinary Syndrome of Menopause: A Systematic Review. Obstetrics & Gynecology. 2014. doi:10.1097/AOG.0000000000000526
- Lukacz ES, Santiago-Lastra Y, Albo ME, et al. Urinary Incontinence in Women: A Review. JAMA. 2017. doi:10.1001/jama.2017.12137
- U.S. Food and Drug Administration. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. FDA News Release. February 12, 2026. fda.gov
← Learn more about Vaginal Estrogen